Implementation of <em>CYP2D6</em> copy-number imputation panel and frequency of key pharmacogenetic variants in Finnish individuals with a psychotic disorder
Häkkinen, Katja; Kiiski, Johanna I.; Lähteenvuo, Markku; Jukuri, Tuomas; Suokas, Kimmo; Niemi-Pynttäri, Jussi; Kieseppä, Tuula; Männynsalo, Teemu; Wegelius, Asko; Haaki, Willehard; Lahdensuo, Kaisla; Kajanne, Risto; Kaunisto, Mari A.; Tuulio-Henriksson, Annamari; Kampman, Olli; Hietala, Jarmo; Veijola, Juha; Lönnqvist, Jouko; Isometsä, Erkki; Paunio, Tiina; Suvisaari, Jaana; Kalso, Eija; Niemi, Mikko; Tiihonen, Jari; Daly, Mark; Palotie, Aarno; Ahola-Olli, Ari V. (2022-02-23)
Häkkinen, K., Kiiski, J.I., Lähteenvuo, M. et al. Implementation of CYP2D6 copy-number imputation panel and frequency of key pharmacogenetic variants in Finnish individuals with a psychotic disorder. Pharmacogenomics J 22, 166–172 (2022). https://doi.org/10.1038/s41397-022-00270-y
© The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
https://creativecommons.org/licenses/by/4.0/
https://urn.fi/URN:NBN:fi-fe2022102162729
Tiivistelmä
Abstract
We demonstrate that CYP2D6 copy-number variation (CNV) can be imputed using existing imputation algorithms. Additionally, we report frequencies of key pharmacogenetic variants in individuals with a psychotic disorder from the genetically bottle-necked population of Finland. We combined GWAS chip and CYP2D6 CNV data from the Breast Cancer Pain Genetics study to construct an imputation panel (n = 902) for CYP2D6 CNV. The resulting data set was used as a CYP2D6 CNV imputation panel in 9262 non-related individuals from the SUPER-Finland study. Based on imputation of 9262 individuals we confirm the higher frequency of CYP2D6 ultrarapid metabolizers and a 22-fold enrichment of the UGT1A1 decreased function variant rs4148323 (UGT1A1*6) in Finland compared with non-Finnish Europeans. Similarly, the NUDT15 variant rs116855232 was highly enriched in Finland. We demonstrate that imputation of CYP2D6 CNV is possible and the methodology enables studying CYP2D6 in large biobanks with genome-wide data.
Kokoelmat
- Avoin saatavuus [32041]